Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 521 participants.
Also called NCT02752828
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 521 participants
- Sponsor
- Registry
-
NCT02752828
-
- Other papers using this trial's data
- Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02752828. Randomized; no masking; primary purpose treatment. Start 2016-05-23 (registry gives no type); primary completion 2018-03-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- Acronym
- LIXILAN JP-O2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Oral anti-diabetic drugs
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02752828- Content hash
93dbe874ba7903db5efb7b58ae92bf22f45acfc47f31bc2674a41c1f26323126